Table 2.

Causes of death and comorbidities as determined by autopsy in six young decedents with COVID-19.

Case	Age	Gender	Symptoms to death	Immediate COD	Condition leading to COD	Underlying cause	Comorbidities/conditions
1	26 years	Male	181 days	Acute mesenteric ischemia	Cholangitis with liver failure	COVID-19 pneumonia	Thromboembolisms of brain vessels Hepatosplenomegaly Pulmonary emphysema Overweight (BMI 28.7 kg/m2)*
2	28 years	Female	16 days	MOF	Invasive pulmonary mycosis	COVID-19 pneumonia	Acute inflammatory cardiomyopathy Mild hepatic steatosis (5–7%)Obesity, WHO °III (BMI 41.2 kg/m 2)*
3	30 years	Female	18 days	Septic MOF	Invasive pulmonary mycosis Intestinal GvHD	Ewing sarcoma followed by t-MDS with therapy-related immunosuppression	SARS-CoV-2 infection Lymphocytic myocarditis Cerebral bleeding Cerebral toxoplasmosis Overweight (BMI 28.1 kg/m2)*
4	33 years	Male	30 days	Hemorrhagic shock after intrathoracic bleeding	Pleural empyema (surgical treatment)	COVID-19 pneumonia	Acute pulmonary thromboembolism Hepatomegaly Heart failure
5	45 years	Female	19 days	Septic MOF	Disseminated intravascular coagulation (pulmonary, intestinal, cerebral)	COVID-19 pneumonia	Hepatic steatosis Coronary artery sclerosis Atherosclerosis
6	46 years	Male	18 days	Heart failure	COVID-19 pneumonia	Dilated cardiomyopathy	Acute pulmonary thromboembolism Chronic cardiac apical thrombus Mild atherosclerosis Overweight (BMI 29.1 kg/m2)*

Abbreviations: cause of death (COD), multi-organ failure (MOF), severe acute respiratory syndrome coronavirus type 2 (SARS CoV-2), coronavirus disease 2019 (COVID-19), body mass index (BMI), *corrected for body cavity effusion), secondary sclerosing cholangitis (SCC), World Health Organization (WHO), graft-versus-host disease (GvHD), therapy-induced myelodysplastic syndrome (t-MDS), allogeneic hematopoietic stem cell transplantation (allo-HSCT).